DNLI
Income statement / Annual
Last year (2023), Denali Therapeutics Inc.'s total revenue was $330.53 M,
an increase of 204.74% from the previous year.
In 2023, Denali Therapeutics Inc.'s net income was -$145.22 M.
See Denali Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$330.53 M
|
$108.46 M
|
$48.66 M
|
$335.66 M
|
$26.68 M
|
$129.16 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$16.73 M |
$7.03 M |
$5.61 M |
$212.62 M |
$193.38 M |
$7.42 M |
$3.08 M |
$1.47 M |
$121,000.00 |
| Gross Profit |
$313.81 M |
$101.43 M |
$43.05 M |
$123.04 M |
-$166.70 M |
$121.75 M |
-$3.08 M |
-$1.47 M |
-$121,000.00 |
| Gross Profit Ratio |
0.95 |
0.94 |
0.88 |
0.37 |
-6.25 |
0.94 |
0 |
0 |
0 |
| Research and Development
Expenses |
$423.88 M
|
$358.73 M
|
$265.35 M
|
$212.62 M
|
$193.38 M
|
$143.18 M
|
$74.46 M
|
$75.70 M
|
$11.57 M
|
| General & Administrative
Expenses |
$103.35 M
|
$90.48 M
|
$79.06 M
|
$60.33 M
|
$46.48 M
|
$32.35 M
|
$15.68 M
|
$11.73 M
|
$5.11 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$103.35 M
|
$90.48 M
|
$79.06 M
|
$60.33 M
|
$46.48 M
|
$32.35 M
|
$15.68 M
|
$11.73 M
|
$5.11 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$527.23 M |
$449.21 M |
$344.41 M |
$272.94 M |
$239.86 M |
$175.53 M |
$90.14 M |
$87.43 M |
$16.68 M |
| Cost And Expenses |
$527.23 M |
$449.21 M |
$344.41 M |
$272.94 M |
$239.86 M |
$175.53 M |
$90.14 M |
$87.43 M |
$16.68 M |
| Interest Income |
$51.51 M |
$14.77 M |
$4.60 M |
$9.14 M |
$15.22 M |
$10.13 M |
$1.96 M |
$781,000.00 |
$0.00 |
| Interest Expense |
$0.00 |
$14.77 M |
$0.00 |
$0.00 |
$15.22 M |
$0.00 |
$1.96 M |
$0.00 |
$109,000.00 |
| Depreciation &
Amortization |
$16.73 M
|
$7.03 M
|
$5.61 M
|
$6.17 M
|
$7.99 M
|
$7.42 M
|
$3.08 M
|
$1.47 M
|
$121,000.00
|
| EBITDA |
-$179.97 M
|
-$330.36 M
|
-$287.16 M
|
$62.72 M
|
-$205.19 M
|
-$38.96 M
|
-$87.06 M
|
-$85.96 M
|
-$15.06 M
|
| EBITDA Ratio |
-0.54 |
-3.05 |
-6.08 |
0.19 |
-7.99 |
-0.36 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.6
|
-3.14
|
-6.08
|
0.19
|
-7.99
|
-0.36
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$51.51 M
|
$14.77 M
|
$4.60 M
|
$9.24 M
|
$15.22 M
|
$10.13 M
|
$1.96 M
|
$781,000.00
|
-$109,000.00
|
| Income Before Tax |
-$145.19 M |
-$325.97 M |
-$291.16 M |
$71.96 M |
-$197.97 M |
-$36.24 M |
-$88.19 M |
-$86.65 M |
-$16.79 M |
| Income Before Tax Ratio
|
-0.44
|
-3.01
|
-5.98
|
0.21
|
-7.42
|
-0.28
|
0
|
0
|
0
|
| Income Tax Expense |
$30,000.00 |
$21,000.00 |
-$575,000.00 |
$823,000.00 |
-$351,000.00 |
$10.13 M |
-$3.08 M |
$0.00 |
$0.00 |
| Net Income |
-$145.22 M |
-$325.99 M |
-$290.58 M |
$71.14 M |
-$197.61 M |
-$36.24 M |
-$88.19 M |
-$86.65 M |
-$16.79 M |
| Net Income Ratio |
-0.44 |
-3.01 |
-5.97 |
0.21 |
-7.41 |
-0.28 |
0 |
0 |
0 |
| EPS |
-1.06 |
-2.6 |
-2.39 |
0.65 |
-2.07 |
-0.39 |
-5.89 |
-13.49 |
-5.58 |
| EPS Diluted |
-1.06 |
-2.6 |
-2.39 |
0.63 |
-2.07 |
-0.39 |
-5.89 |
-13.49 |
-5.58 |
| Weighted Average Shares
Out |
$137.37 M
|
$125.53 M
|
$121.52 M
|
$108.97 M
|
$95.61 M
|
$92.62 M
|
$14.96 M
|
$6.42 M
|
$3.01 M
|
| Weighted Average Shares
Out Diluted |
$137.37 M
|
$125.53 M
|
$121.52 M
|
$112.70 M
|
$95.61 M
|
$92.62 M
|
$14.96 M
|
$6.42 M
|
$3.01 M
|
| Link |
|
|
|
|
|
|
|
|
|
